Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease encephalopathy
Phenotype C0023895|liver disease
Sentences 28
PubMedID- 24133449 Alf results from the acute and rapid loss of hepatocyte function, and is associated with coagulopathy [international normalized ratio (inr) >1.5] and hepatic encephalopathy (he) in a patient without pre-existing liver disease.
PubMedID- 22867045 All opioid drugs can precipitate or aggravate hepatic encephalopathy in patients with severe liver disease, thus requiring cautious use and careful monitoring.
PubMedID- 25908985 These include hepatic encephalopathy in patients with advanced liver disease, vascular bypass of the liver, valproic acid or cyclophosphamide poisoning, herpes simplex infection, and gastrointestinal bacterial overgrowth.
PubMedID- 21705899 Objective: hyperammonemia is a major contributing factor to the encephalopathy associated with liver disease.
PubMedID- 20335583 Methods: in this randomized, double-blind, placebo-controlled trial, we randomly assigned 299 patients who were in remission from recurrent hepatic encephalopathy resulting from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice daily (140 patients), or placebo (159 patients) for 6 months.
PubMedID- 24498036 Considered non-aids events included non-aids malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (>grade 3), cardio- and cerebrovascular events, and end-stage renal disease.
PubMedID- 25068951 Acute liver failure (alf) is an uncommon clinical syndrome that often has a course associated with rapidly progressive multiorgan failure and devastating complications like coagulopathy and encephalopathy in patients without previous liver disease.
PubMedID- 23150814 Alf is defined as the rapid development of hepatocellular dysfunction, specifically coagulopathy and mental status changes (encephalopathy) in a patient without known prior liver disease and with an illness of <24 weeks duration.
PubMedID- 25733099 The primary outcome was drug-induced alf (defined as coagulopathy and hepatic encephalopathy without underlying chronic liver disease), determined by hepatologists who reviewed medical records of all kpnc members with inpatient diagnostic and laboratory criteria suggesting potential alf.
PubMedID- 23936100 This characteristic profile is typical of hepatic encephalopathy associated with chronic liver disease and portosystemic shunting [8], [9], [10], [11], [12], [13], [15].
PubMedID- 26426612 Hepatitis b virus (hbv) infection is a global health problem, with a seroprevalence varying from 1.7% (latin america) to 11.3% (east asia and pacific).1 hbv infection is associated with an increased risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma.2 hepatic decompensation may be gradual or acute, which is termed acute-on-chronic liver failure (aclf).3 patients with chronic hepatitis b (chb) may experience a severe acute exacerbation of the disease that progresses into liver failure, which is defined as acute-on-chronic hepatitis b liver failure (achblf), manifesting as jaundice and coagulopathy (international normalized ratio [inr] > 1.5) complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic liver disease.3,4 liver transplantation is the only curative therapeutic option for aclf, with a 5-year survival rate of 85%.
PubMedID- 25867912 Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
PubMedID- 22447259 Acute liver failure (alf) (sometimes referred to as fulminant hepatic failure) is a clinical syndrome from a variety of causes resulting from rapid loss in hepatocyte function, typically associated with coagulopathy and encephalopathy in a patient without preexisting liver disease or cirrhosis.
PubMedID- 26098218 In the intestine, bacterial urease converts host-derived urea to ammonia and carbon dioxide, contributing to hyperammonemia-associated neurotoxicity and encephalopathy in patients with liver disease.
PubMedID- 25374704 Metronidazole-induced encephalopathy in a patient with end-stage liver disease.
PubMedID- 26029995 Objectives: acute liver failure is a life-threatening condition with sudden onset liver injury, decreased liver functions, hepatic encephalopathy, and coagulopathy in patients without preexisting liver disease.
PubMedID- 24367215 The definition of hepatic encephalopathy is difficult in patients with alcoholic liver disease who have initial neurologic manifestations as part of diffuse central and peripheral neuropathy.
PubMedID- 21384402 Additional studies are warranted to evaluate the effects of ast-120 on hepatic encephalopathy in patients with advanced liver disease.
PubMedID- 24665321 The sudden onset and rapid reversibility of encephalopathy in liver disease suggest that it has a metabolic origin, so that the liver cannot detoxify the portal venous blood.
PubMedID- 22228885 The aim of this study was to evaluate scientific evidence for the effectiveness and safety of lola infusions for treatment of clinical hepatic encephalopathy in patients with chronic liver disease.
PubMedID- 20728575 No state specifically mentioned hepatic encephalopathy or patients with advanced liver disease.
PubMedID- 20880508 Many theories have been advanced to explain the encephalopathy associated with chronic liver disease and with the less common acute form.
PubMedID- 25849554 Briefly, acute hepatic injury manifestated as increasing jaundice (serum tbil>85 umol/l) and coagulopathy (pta <40%) in patients with previously diagnosed or undiagnosed chronic liver diseases, complicated by ascites and/or encephalopathy within 4 weeks.
PubMedID- 25374719 Acute liver failure is characterized by the rapid development of severe liver injury with impaired synthetic function and hepatic encephalopathy in a patient without obvious, previous liver disease.
PubMedID- 21741091 Rifaximin received new labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (he) in patients with advanced liver disease in march of 2010.
PubMedID- 25586470 Objectives: rifaximin is approved for the reduction of hepatic encephalopathy (he) recurrence in patients with chronic liver disease (cld); however, few studies have evaluated the benefit of adding rifaximin to lactulose for treatment of acute he.
PubMedID- 23978689 Alf is characterized by coagulopathy and hepatic encephalopathy (he) in a patient without pre-existing liver disease.
PubMedID- 21959704 Minimal encephalopathy was originally associated with chronic liver disease but is increasingly associated with most other chronic diseases and particularly with diabetes and also chronic disorders in other organs: kidneys, lungs, thyroid and with obesity.

Page: 1